Skip to main content
Atrás
SPRY logo

ARS Pharmaceuticals, Inc.

Calidad de datos: 100%
Sobreventa
SPRY
NASDAQ Healthcare Biotechnology
$7.67
▼ $0.50 (-6.12%)
Cap. Mercado: 761.61M
Rango del Día
$7.60 $8.48
Rango de 52 Semanas
$6.66 $18.90
Volumen
1,754,266
Promedio 50D / 200D
$9.69 / $11.76
Cierre Anterior
$8.17

Historial de Precios

Tendencias Financieras

Comparación con Pares

vs mediana del sector Healthcare (626 pares)

Métrica Acción Mediana del Sector
P/E -4.5 0.4
P/B 6.7 2.9
ROE % -92.3 3.7
Net Margin % -203.3 3.8
Rev Growth 5Y % 97.8 10.0
D/E 0.9 0.2

Insider Trading Activity

20 transactions
Date Insider Type Shares Price Value
Jan 2, 2026
Dorsey Brian
Chief Operating Officer
grant 240,000
Jan 2, 2026
Chakma Justin
Chief Business Officer
grant 240,000
Jan 2, 2026
Scott Kathleen D.
Chief Financial Officer
grant 240,000
Jan 2, 2026
Lowenthal Richard E
PRESIDENT AND CEO
grant 1,115,000
Jan 2, 2026
Tanimoto Sarina
CHIEF MEDICAL OFFICER
grant 1,115,000
Nov 13, 2025
Dorsey Brian
Chief Operating Officer
other 43,656 $0.64
Nov 13, 2025
Dorsey Brian
Chief Operating Officer
sell 21,828 $8.71 $190,050
Aug 21, 2025
Scott Kathleen D.
Chief Financial Officer
other 25,000 $1.50
Aug 21, 2025
Scott Kathleen D.
Chief Financial Officer
sell 12,500 $15.00 $187,500
Jul 1, 2025
Karas Eric
Chief Commercial Officer
other 30,000 $1.50
Jul 1, 2025
Karas Eric
Chief Commercial Officer
sell 15,000 $16.99 $254,861
Jun 25, 2025
Shawver Laura
grant 30,000
Jun 25, 2025
Islam Saqib
grant 30,000
Jun 25, 2025
Shah Pratik
grant 30,000
Jun 25, 2025
Dadoo Rajeev
grant 30,000
Jun 25, 2025
Kelly Michael
grant 30,000
Jun 25, 2025
SAUNDERS BRENT L
grant 30,000
Jun 18, 2025
Karas Eric
Chief Commercial Officer
other 30,000 $1.50
Jun 18, 2025
Karas Eric
Chief Commercial Officer
sell 15,000 $16.00 $240,000
May 20, 2025
SAUNDERS BRENT L
other 240,000 $1.01

Puntos Clave

Revenue grew 97.80% annually over 5 years — strong growth
Earnings declined -2241.76% over the past year
Negative free cash flow of -171.21M
PEG of 0.00 suggests growth is underpriced
Revenue growth is decelerating — 1Y growth trails 5Y average by 103.26%
Capital efficient — spends only 0.40% of revenue on capex

Crecimiento

Revenue Growth (5Y)
97.80%
Revenue (1Y)-5.46%
Earnings (1Y)-2241.76%
FCF Growth (3Y)N/A

Calidad

Return on Equity
-92.33%
ROIC-63.72%
Net Margin-203.25%
Op. Margin-212.92%

Seguridad

Debt / Equity
0.85
Current Ratio7.28
Interest Coverage-69.05

Valoración

P/E Ratio
-4.45
P/B Ratio6.67
EV/EBITDAN/A
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) -5.46% Revenue Growth (3Y) 5200.25%
Earnings Growth (1Y) -2241.76% Earnings Growth (3Y) N/A
Revenue Growth (5Y) 97.80% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 84.28M Net Income (TTM) -171.30M
ROE -92.33% ROA -52.28%
Gross Margin 75.77% Operating Margin -212.92%
Net Margin -203.25% Free Cash Flow (TTM) -171.21M
ROIC -63.72% FCF Growth (3Y) N/A
Safety
Debt / Equity 0.85 Current Ratio 7.28
Interest Coverage -69.05 Dividend Yield 0.00%
Valuation
P/E Ratio -4.45 P/B Ratio 6.67
P/S Ratio 9.04 PEG Ratio 0.00
EV/EBITDA N/A Dividend Yield 0.00%
Market Cap 761.61M Enterprise Value 817.26M

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 84.28M 89.15M 30,000.0 1.32M 5.51M
Net Income -171.30M 8.00M -54.37M -34.68M -20.24M
EPS (Diluted) -1.74 0.08 -0.57 -0.87 -0.70
Gross Profit 63.86M 68.59M 30,000.0 1.32M 5.29M
Operating Income -179.45M -3.08M -67.52M -35.52M -19.45M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 327.65M 351.15M 233.19M 281.44M 61.45M
Total Liabilities 213.39M 94.36M 2.43M 8.55M 92.72M
Shareholders' Equity 114.26M 256.80M 230.76M 272.89M -31.27M
Total Debt 96.96M 42,000.0 274,000.0 481,000.0 9.03M
Cash & Equivalents 41.32M 50.82M 70.97M 210.52M 60.06M
Current Assets 284.90M 334.30M 231.56M 277.70M 60.73M
Current Liabilities 39.15M 23.44M 2.39M 5.44M 8.19M